AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CinCor Pharma

AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.

AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal

The Food and Drug Administration late Friday said that AstraZeneca Plc's AZN, +1.42% COVID-19 drug Evusheld may not provide protection against developing the illness in people exposed to XBB.1.5, one of the newest COVID subvariants. That's because XBB.1.5 is similar to other subvariants not neutralized by Evusheld, the FDA said.

AstraZeneca's COVID drug Evusheld unlikely to neutralize newest variant, FDA says

The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.

FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA

Biogen

These two stocks might go in different directions in the future.

1 Stock Defying the Downturn to Buy, and 1 to Avoid

GlaxoSmithKline

The global pharma sector is expected to see clinical trial readouts that could potentially de-risk approximately US$74bn of peak sales in 2023, according to a research report from Credit Suisse, This is in comparison to US$102bn of readouts in 2022 and US$78bn in 2021, excluding COVID-19-related treatments. The report also found that a record proportion of the 2023 readouts, approximately 40%, will come from line extensions where a drug is already approved for use in a different disease setting.

GSK, AstraZeneca: Will the two UK drugs giants ride the US$74bn pharma wave or will they be left beached?

CHICAGO--( BUSINESS WIRE )--Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), that aims to identify biomarkers of response in patients with small cell lung cancer (SCLC). The study, titled Sculptor, is co-sponsored by Tempus and AstraZeneca's Personalize SCLC Initiative and is currently open for enrollment.

Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

A phase III clinical trial of a lung cancer drug developed by AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo is expected to show positive results, according to a leading investment bank. The treatment, called Dato-DXd, is being tested in patients with non-small cell lung cancer (NSCLC) and is aimed at improving progression-free survival (PFS).

AstraZeneca: Has the market factored in the full value of potential cancer blockbuster?

Ahead of Dato-DXd TL01 study data, expected to be published by AstraZeneca PLC (LSE:AZN) by the end of Q1 2023, analysts at JPMorgan see a high positive "which should unlock multi-blockbuster potential". The analysts said they see a positive readout from the Phase III study in second-line non-small cell lung cancer (NSCLC) patients, de-risking around $3bn in peak potential in second-line NSCLC.

AstraZeneca Dato-DXd TL01 study data expected to be a high positive "which should unlock multi-blockbuster potential" - analysts

Caterpillar

e.l.f. Beauty

As last year's bear market spills over into 2023, breakout index stocks like CAT, BOX, AZN and ELF stock show resilience. The post Which Stocks Show Thick Skin As Bears Sink Fangs Into New Year?

Which Stocks Show Thick Skin As Bears Sink Fangs Into New Year?

TOKYO & MUNICH--( BUSINESS WIRE )--Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy.

ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer

AbbVie

Abbott Labs

Alnylam Pharmaceuticals

Amgen

argenx

Baxter

Bayer AG

BeiGene

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Gilead Sciences

Genmab - ADR

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Eli Lilly

Merck

Moderna

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Pfizer

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Royalty Pharma

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

Vertex Pharmaceuticals

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.

AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers

Japan just approved three drugs against cancer and leukemia. AstraZeneca increased its 2022 guidance.

AstraZeneca: Our 2023 Growth Pick

Broadcom

Innovative Industrial Properties

NextEra Energy

Novavax

You don't need a mountain of money to grow your wealth on Wall Street.

Got $1,000? 5 Sensational Stocks to Buy to Start 2023 With a Bang

The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.

AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs

The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.

AstraZeneca (AZN) Gets EU Nod & CHMP Opinions for Some Drugs

AstraZeneca's new asthma rescue treatment could soon be approved in the United States for adults.

Could AstraZeneca's Asthma Drug Candidate Generate Billions?

AstraZeneca shares slipped as it reported mixed results from its latest trial (PEARL) of the cancer drug Imfinzi. Using Imfinzi as a single therapy for lung cancer sufferers, the drug missed its primary endpoint of improving survival rates among patients with stage IV metastatic disease and showing high levels (25%) of the biomarker PD-L1.

AstraZeneca posts mixed results from lung cancer trial

AstraZeneca PLC said Monday that its Forxiga drug has been recommended for approval in the European Union for certain types of heart failure.

AstraZeneca's Forxiga gets EU approval recommendation for symptomatic chronic heart failure

AstraZeneca's Imfinzi plus Imjudo recommended for approval in the EU

TOKYO & MUNICH--( BUSINESS WIRE )--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low Metastatic Breast Cancer

TOKYO & MUNICH--( BUSINESS WIRE )--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

ENHERTU® Approved in the EU for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer

The FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for Lynparza's indication in prostate cancer. The FDA intends to use this time to review the submission.

FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA

AstraZeneca PLC (LSE:AZN), and its US peer Merck & Co, announced that the US Food and Drug Administration (FDA) will allow more time to review the new drug application for its cancer drug, Lynparza. The pharmaceuticals giant said the FDA will extend the Prescription Drug User Fee Act (PDUFA) date by three months to provide further time for a full review of the supplementary new drug application for Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment ofmetastatic castration-resistant prostate cancer.

AstraZeneca's new drug application for Lynparza given more time by US FDA

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Johnson & Johnson (JNJ), Novo Nordisk (NVO), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.

4 Large Drug Stocks to Watch in a Booming Industry

News for AstraZeneca Stock (AZN)